INTC vs PFE: Which Is the Better Buy?
Side-by-side comparison of Intel Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
Intel Corporation · Technology
$68.50
-13.9% upside to fair value
High Conviction
Grade D
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
PFE has more upside to fair value
(+30.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTC |
PFE |
| Current Price |
$68.50 |
$26.91 |
| Fair Value Estimate |
$59.00 |
$35.00 |
| Upside to Fair Value |
-13.9%
|
+30.1%
|
| Market Cap |
$343.9B |
$153.0B |
| Forward P/E |
-1245.8x
|
9.5x
|
| EV / EBITDA |
—
|
13.8x
|
| Price / Sales |
6.5x
|
2.4x
|
| Price / FCF |
-69.5x
|
16.8x
|
| Revenue Growth YoY |
+0.2%
|
-1.6%
|
| Gross Margin |
34.8%
|
70.3%
|
| Operating Margin |
-4.2%
|
24.7%
|
| Return on Equity |
-0.3%
|
9.0%
|
| Dividend Yield |
— |
6.4% |
| FCF Yield |
—
|
5.9%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Intel is a legacy semiconductor leader attempting an ambitious turnaround under new CEO Lip-Bu Tan, pivoting from a pure-play chipmaker to an integrated device manufacturer (IDM 2.0) with foundry ambitions. The business remains structurally challenged: PC market share is eroding, foundry execution is unproven, negative free cash flow persists, and margins are compressed. However, the stock trades…
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
| Metric |
INTC |
PFE |
| Zone Low |
$44.00 |
$25.00 |
| Zone High |
$50.00 |
$29.00 |
| In Buy Zone? |
No
|
Yes
|